BiotechTube
Charleston Laboratories

Charleston Laboratories

Marlton, United States· Est.
charlestonlabs.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $35M

Overview

Charleston Laboratories is a private, clinical-stage biotech company pioneering a novel approach to acute pain management by co-formulating analgesics with antiemetics to mitigate debilitating side effects. The company's lead asset, CL-108, has completed Phase 3 studies and has resubmitted an NDA, positioning it as a near-term potential commercial product. With a focused pipeline built on its proprietary technology platform, Charleston aims to shift the treatment paradigm in acute pain care by improving patient tolerability and recovery.

Acute Pain ManagementSupportive Care (Nausea/Vomiting)

Technology Platform

Proprietary platform for fixed-dose combination products featuring differentiated release mechanisms that deliver an antiemetic agent first, followed by a modified-release analgesic, designed to prevent drug-induced nausea and vomiting.

Funding History

2
Total raised:$35M
Debt$20M
Series A$15M

Opportunities

The primary opportunity is addressing the vast unmet need in acute pain, where 40% of opioid-treated patients suffer from nausea and vomiting, often leading to poor compliance and recovery.
Successful approval and launch of CL-108 could capture a significant share of the millions of annual opioid prescriptions by offering a differentiated tolerability profile.
The technology platform also allows for expansion into other therapeutic areas where drug- or disease-induced emesis is a problem, such as chemotherapy, migraines, and postoperative care.

Risk Factors

The company faces significant regulatory risk with its resubmitted NDA for CL-108 and commercial execution risk as a first-time launcher in the highly competitive and scrutinized opioid market.
Broader market risks include increasing restrictions on opioid prescribing and societal pressure to reduce opioid use, which could limit the addressable market regardless of the product's antiemetic benefits.

Competitive Landscape

Competition is intense, including generic immediate-release opioids, standalone antiemetics, and other branded combination products or abuse-deterrent formulations. The key differentiator for Charleston is its specific focus on preemptively preventing nausea/vomiting via a single-tablet, timed-release combination, a niche not fully addressed by current standard of care which relies on separate, often ineffective, dosing of antiemetics.

More companies in Small Molecule Drugs →More companies in United States →